-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Studies have shown that gray matter (GM) atrophy measured on MRI in patients with multiple sclerosis (MS) reflects irreversible axonal loss and neurodegenerative changes in the central nervous system
Studies have shown that gray matter (GM) atrophy measured on MRI in patients with multiple sclerosis (MS) reflects irreversible axonal loss and neurodegenerative changes in the central nervous system
There are many methods and software currently available to measure GM atrophy
Because of the high tissue contrast of non- enhanced three-dimensional (3D) T1-weighted images, brain segmentation software often uses this sequence of images for evaluation .
The use of GBCA has increased over the past three decades
A study published in the journal European Radiology validates volume and cortical thickness measurements using GBCA -enhanced T1-weighted images and provides guidance on how to interpret clinically relevant and commonly considered measurements .
There was good to excellent reliability between all survey measures, with ICC ranging from 0.
This study demonstrates that FreeSurfer can obtain reliable GM atrophy measurements from enhanced three-dimensional T1-weighted images .
Original source :
Ingrid Anne Lie , Emma Kerklingh , Kristin Wesnes ,et al .
Ingrid Anne Lie Emma Kerklingh Kristin Wesnes ,et al The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis 10.
1007/s00330-021-08405-8 10.
1007/
s00330-021-08405-8in this message